Research Bridge Partners
Research Bridge Partners is a non-profit organization based in Austin, Texas, dedicated to enhancing the societal and economic impact of research universities in the mid-continent region of the United States. Founded by Isaac Barchas and Reid Hoffman, the organization connects university innovators with commercialization resources across the country. It manages a seed fund that exclusively accepts program-related investments from other charitable entities to support its tax-exempt charitable, educational, and scientific objectives. By focusing on strategic startup creation, Research Bridge Partners aims to advance scientific research in the public interest, ensuring that innovations from mid-continent universities contribute to broader societal benefits.
Top Stages
4 past transactions
Tetricus Labs
Seed Round in 2023
Tetricus Labs is a precision psychiatry company that employs advanced AI computational neuroscience to deliver accurate patient diagnoses and tailored treatment recommendations for various mental health conditions.
UT Southwestern Medical Center
Grant in 2023
The UT Southwestern Medical Center provides patient care, research facilities, and academic medical centers. They offer cutting-edge therapies, treatments, and first-rate specialized care.
Asalyxa Bio
Seed Round in 2021
Asalyxa Bio, Inc. is a drug development and platform technology company based in Southfield, Michigan, focusing on innovative therapeutics to address significant unmet medical needs linked to immune signaling dysregulation. The company specializes in developing neutrophil-targeting drugs aimed at combating severe neutrophil-mediated diseases, including conditions like Covid-19. Asalyxa Bio's platform technology facilitates the targeted delivery of both existing and novel drugs directly into over-reactive immune cells, thereby enhancing treatment efficacy. This approach allows for applications across a diverse range of diseases and conditions, positioning Asalyxa Bio as a key player in the field of immunotherapy.
Novosteo
Seed Round in 2019
Novosteo Inc. is a biotechnology company based in West Lafayette, Indiana, founded in 2017. The firm specializes in developing and manufacturing innovative drugs aimed at healing bone fractures and addressing related conditions that significantly impact patients' morbidity, mortality, and quality of life. With scientific guidance from co-founders Stewart Low and Philip Low of Purdue University, Novosteo utilizes a proprietary chemistry approach to bone targeting, which allows for the delivery of anabolic agents directly to fracture surfaces. This unique method focuses on accelerating bone regeneration and improving healing outcomes, thereby mitigating the debilitating effects associated with bone injuries and enhancing patient mobility and productivity.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.